FIELD: medicine, endocrinology, pharmacy.
SUBSTANCE: invention relates to a pharmaceutical compound used for preparing a medicinal agent for reducing plasma blood glucagon level in a patient. Compound is taken among a group consisting of eczendin, its analog, modified eczendin and modified eczendin analog wherein indicated compound involves at least 31 modified amino acids occurring in the nature. Invention provides reducing level of glucagons and/or inhibition of glucagons in both insulin-dependent (type 1) and non-insulin-dependent (type 2) of diabetes mellitus.
EFFECT: improved inhibiting method, valuable medicinal properties of agent.
15 cl, 27 dwg
Title | Year | Author | Number |
---|---|---|---|
METHODS OF DIABETES TREATMENT AND BODY WEIGHT REDUCTION | 2006 |
|
RU2421237C2 |
METHODS FOR DELIVERY OF NEUROPROTECTIVE POLYPEPTIDE TO CENTRAL NERVOUS SYSTEM | 2017 |
|
RU2790566C2 |
COMPOSITION AND MICROSPHERE WITH CONTROLLED EXENDIN RELEASE AND METHOD OF OBTAINING MICROSPHERE | 2008 |
|
RU2463040C2 |
METHODS AND COMPOSITIONS FOR TREATING GASTROINTESTINAL DISORDERS | 2004 |
|
RU2543350C2 |
NEW COMPOSITIONS OF EXENDINE AGONISTS AND METHODS OF THEIR ADMINISTRATION | 2000 |
|
RU2242244C2 |
METHODS AND COMPOSITIONS FOR GASTROENTERIC UPSET THERAPY | 2004 |
|
RU2353383C2 |
METHODS AND COMPOSITIONS FOR TREATMENT OF GASTROINTESTINAL DISORDERS | 2014 |
|
RU2763796C2 |
COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | 2014 |
|
RU2771808C2 |
INSULIN ANALOGUE COMPLEX WITH REDUCED AFFINITY TO INSULIN RECEPTOR AND ITS USE | 2018 |
|
RU2779462C2 |
INSULIN ANALOGUES WITH REDUCED AFFINITY TO INSULIN RECEPTOR AND THEIR USE | 2017 |
|
RU2764197C1 |
Authors
Dates
2005-03-10—Published
2000-01-14—Filed